Skip to main content
OpenTrials
Completed

NCT Number: NCT01428024

Study to Evaluate Efficacy, Safety and Injection Technique of Restylane Lip Volume and Restylane Lip Refresh

The purpose of this study is to demonstrate the efficacy and safety of two new Restylane Lip products, Restylane Lip Volume and Restylane Lip Refresh, and to collect information on the injection technique.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Göteborgs Plastikkirurgiska Center, Gothenburg, Sweden

Loading trial locations.

About this study

Restylane Lip Volume is intended to be used for lip enhancement and Restylane Lip Refresh is intended to restore hydrobalance and improve skin structure of the lips (referred to as lip rejuvenation in this protocol), respectively. The lidocaine content is designed to reduce the subject's pain during treatment. The objectives of this open, multicenter study are to evaluate efficacy and safety of the products for the studied indications and to collect information on injection techniques used.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 to 60 years of age.
  • Intent to undergo lip augmentation or rejuvenation of both the upper and lower lip.
  • Signed informed consent.

Exclusion criteria

  • Prior surgery or tattoo to the upper or lower lip or lip line.
  • Presence of any abnormal lip structure, such as a scar or lump or severe lip asymmetry.
  • A history of herpes labialis and an outbreak within four weeks of study entry or with four or more outbreaks in the 12 months prior to study entry.
  • Presence of facial hair that may interfere with efficacy evaluations.
  • Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or on the area to be treated.
  • History of angioedema.
  • Previous hypersensitivity to hyaluronic acid or local anesthetics.
  • Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation within 10 days prior to treatment, or a history of bleeding disorders.
  • Cancerous or pre-cancerous lesions in the area to be treated.
  • Previous tissue augmenting therapy in the area to be treated with hyaluronic acid (HA) or collagen filler, or laser treatment, during the last 12 months.
  • Permanent implant placed in the area to be treated or treatment with non-HA or non-collagen filler in the area to be treated.
  • Pregnancy or breast feeding.
  • Participation in any other clinical study within 30 days prior to inclusion.
  • Other condition preventing the subject to entering the study in the Investigator's opinion e.g. subjects not likely to avoid other facial cosmetic treatments below the level of the lower orbital rim, subjects anticipated to be unreliable or incapable of understanding the study assessment or unrealistic expectations of treatment result.
  • Study staff or close relative to study staff (e.g. parents, children, siblings or spouse).

Treatment and study plan

Restylane Lip Volume

Device

Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.

Restylane Lip Refresh

Device

Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.

Primary outcomes

  1. GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 8 After Treatment

    Time frame: At week 8 - change of lips from baseline

    To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.

Secondary outcomes

  1. GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 36 After Treatment

    Time frame: week 36 - change from baseline

    To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.

  2. GEIS (Global Esthetic Improvement Scale) Assessed by the Treating Investigator at Week 36 After Treatment

    Time frame: week 36 - change from baseline

    To evaluate esthetic change of lips from baseline as judged by the treating investigator using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change.

  3. GEIS (Global Esthetic Improvement Scale) Assessed by the Independent Evaluator at Week 36 After Treatment

    Time frame: week 36 - change from baseline

    To evaluate esthetic change of lips from baseline as judged by the independent evaluator using GEIS at week 2, 4, 12, 26 and 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.

  4. MLFS (Medicis Lip Fullness Scale) at Week 8

    Time frame: week 8 - change from baseline

    To evaluate the efficacy in terms of Medicis Lip Fullness Scale (MLFS) score by live assessment performed separately by the treating and the independent investigators in the Restylane Lip Volume group. The scale has five levels: Very thin, thin, median, full, very full. Treatment success is defined as at least one grade increase.

  5. Subject Satisfaction Questionnaire

    Time frame: Week 8

    To evaluate subjects satisfaction in terms of a subject satisfaction questionnaire at week 8 after treatment.

    The subject satisfaction questionnaire consists of questions regarding the looks, appearance, disomfort, and satisfaction regarding the treatment of the lips.

    The question that will be referred to is: How satisfied are you today with (the look of) your lips ?

  6. Subject Diary for 14 Days After Initial Treatment

    Time frame: 2 weeks after initial treatment

    To evaluate the acute safety profile (bruising, itching, pain, redness, swelling and tenderness) in terms of a 14-day subject diary after initial treatment.

    Subjects still reporting one or more of the symptoms; bruising, itching, pain, redness, swelling and tenderness in the diary at day 14.

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Official study title

An Open, Multi-center Study Evaluating Efficacy, Safety and Injection Technique of Restylane Lip Products for Lip Enhancement and Lip Rejuvenation

Important dates

Study start
2011
Primary completion
2011
Study completion
2012
First posted
Sep 2, 2011
Registry last updated
Aug 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.